BA
APTO

Boston Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Boston Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40
Closed -$47K – 642
2019
Q2 		$47K Hold
40
– – ﹤0.01% 630
2019
Q1 		$36K Buy
+40
New +$36.2K ﹤0.01% 630

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Boston Advisors's APTO Position: Q3 2019 in Review

Boston Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q3 2019, closing a stake of 40 shares — an estimated $47K sold.

Boston Advisors first reported a position in APTO in Q1 2019 and held it in 2 quarters. The position peaked at $47K in Q2 2019. 31 funds tracked by Wall St. Rank hold APTO as of Q3 2019.

  • Boston Advisors reported no remaining Aptose Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
  • Boston Advisors sold 40 Aptose Biosciences, Inc. shares in Q3 2019, an estimated $47K.
  • Boston Advisors first reported a position in Aptose Biosciences, Inc. in Q1 2019 and held it in 2 quarters.
  • Boston Advisors's Aptose Biosciences, Inc. position peaked at $47K in Q2 2019.
  • 31 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.